| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_9953d04005af6bdc453c3a58c2a4e4fb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_563b4ef76483b92873a03238ba91cefa
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f061c4d406c8aa29b4d3688da9ca51d0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cec77301991988cc056a48f7a922c7df
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0adc0c2b4b9f0c8b3c5f32563b4befcb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3239da6c03c42b13547f0e1ad2dbaef1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f7cd94afb2c9789fa5ee89d3b345586a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_be51a9b5cb9a7c0a25912db33245b334
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f2d3599fb8f8f479dba95ca9bb504884 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12Q1-6809 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12Q1-68 |
| filingDate |
2006-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f88e7c68118a9337151143192291bbc7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_93995989e5ddc77d549fc91665a14b18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_81caacc49cacd0c053f2ef468d1d14ff
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b7a70978891368c4408ddf0e6708668d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f2b1cafcbc4d31bfaa9bf60f8cf39e48
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_83381707437629ad8188ebcd7682082c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e6d2d3d4e42349dcb1052313ba3997ab |
| publicationDate |
2006-08-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2006085065-A2 |
| titleOfInvention |
Vagal afferent neurons as targets for treatment |
| abstract |
A method of identifying a compound capable of reducing or preventing prolonged sensory neuron hyper-excitability comprising the steps of: (a) administering the compound to an experimental non-human animal having prolonged sensory neuron hyper-excitability; (b) generating an expression profile of the genes modulated in the Nodose Ganglia (NG) of the animal of step (a); (c) comparing the expression profile obtained in (b) with the expression profile of a corresponding panel of genes expressed in the NG of an experimental non-human animal having no prolonged sensory neuron hyper-excitability; wherein a positive correlation of the expression profiles is indicative that the compound is capable of reducing or preventing prolonged sensory neuron hyper-excitability in NG. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106834429-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-2390349-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106834429-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011147851-A1 |
| priorityDate |
2005-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |